{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+4&page=49",
    "query": {
      "intervention": "cohort 4",
      "page": 49
    },
    "page_size": 10
  },
  "pagination": {
    "page": 49,
    "page_size": 10,
    "total_count": 3785,
    "total_pages": 379,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+4&page=50&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+4&page=48&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T09:39:53.948Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04263181",
      "title": "AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Peripheral blood draw",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone marrow aspirate",
          "type": "PROCEDURE"
        },
        {
          "name": "Buccal swab",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2020-01-29",
      "completion_date": "2027-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-11-19T09:39:53.948Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04263181"
    },
    {
      "nct_id": "NCT03921528",
      "title": "An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Spinal Muscular Atrophy",
        "Spinal Muscular Atrophy Type 3",
        "Spinal Muscular Atrophy Type 2",
        "SMA",
        "Neuromuscular Diseases",
        "Muscular Atrophy",
        "Atrophy",
        "Muscular Atrophy, Spinal",
        "Neuromuscular Manifestations"
      ],
      "interventions": [
        {
          "name": "SRK-015",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Scholar Rock, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "2 Years to 21 Years"
      },
      "enrollment_count": 58,
      "start_date": "2019-04-22",
      "completion_date": "2024-02-28",
      "has_results": true,
      "last_update_posted_date": "2024-12-02",
      "last_synced_at": "2026-11-19T09:39:53.948Z",
      "location_count": 11,
      "location_summary": "Phoenix, Arizona • Palo Alto, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03921528"
    },
    {
      "nct_id": "NCT02736565",
      "title": "Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ewing's Sarcoma",
        "Ewing Family of Tumors",
        "Ewing's Tumor Metastatic",
        "Ewing's Sarcoma Metastatic",
        "Ewing's Tumor Recurrent",
        "Rare Diseases",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "pbi-shRNA™ EWS/FLI1 Type 1 Lipoplex",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Gradalis, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "8 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2016-10",
      "completion_date": "2020-08-04",
      "has_results": false,
      "last_update_posted_date": "2023-11-13",
      "last_synced_at": "2026-11-19T09:39:53.948Z",
      "location_count": 2,
      "location_summary": "New York, New York • Dallas, Texas",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02736565"
    },
    {
      "nct_id": "NCT04544592",
      "title": "UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "B-cell Acute Lymphoblastic Leukemia",
        "B-cell Non Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "31 Days",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "31 Days to 30 Years"
      },
      "enrollment_count": 45,
      "start_date": "2021-03-10",
      "completion_date": "2031-03-10",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-11-19T09:39:53.948Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04544592"
    },
    {
      "nct_id": "NCT02414139",
      "title": "Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Capmatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 373,
      "start_date": "2015-06-11",
      "completion_date": "2023-05-16",
      "has_results": true,
      "last_update_posted_date": "2024-03-20",
      "last_synced_at": "2026-11-19T09:39:53.948Z",
      "location_count": 13,
      "location_summary": "Long Beach, California • Los Angeles, California • Orange, California + 10 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02414139"
    },
    {
      "nct_id": "NCT00304200",
      "title": "Temodar and Sutent as Therapy for Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Malignant Melanoma"
      ],
      "interventions": [
        {
          "name": "Temozolomide and SU11248",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northern California Melanoma Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2006-03",
      "completion_date": "2009-01",
      "has_results": false,
      "last_update_posted_date": "2009-02-05",
      "last_synced_at": "2026-11-19T09:39:53.948Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00304200"
    },
    {
      "nct_id": "NCT07104799",
      "title": "Momelotinib During and After HCT in Myelofibrosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myelofibrosis",
        "Hematopoietic Cell Transplantation (HCT)"
      ],
      "interventions": [
        {
          "name": "Momelotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2026-02-23",
      "completion_date": "2030-01",
      "has_results": false,
      "last_update_posted_date": "2026-11-17",
      "last_synced_at": "2026-11-19T09:39:53.948Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07104799"
    },
    {
      "nct_id": "NCT06453265",
      "title": "A Study to Assess the Abuse Potential of Intranasal Cebranopadol",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Abuse, Drug"
      ],
      "interventions": [
        {
          "name": "Cebranopadol- 600 ug",
          "type": "DRUG"
        },
        {
          "name": "Cebranopadol- 800ug",
          "type": "DRUG"
        },
        {
          "name": "Cebranopadol- 1000ug",
          "type": "DRUG"
        },
        {
          "name": "Treatment A:",
          "type": "DRUG"
        },
        {
          "name": "Treatment B",
          "type": "DRUG"
        },
        {
          "name": "Treatment C",
          "type": "DRUG"
        },
        {
          "name": "Qualification",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tris Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 48,
      "start_date": "2024-06-28",
      "completion_date": "2024-11-06",
      "has_results": false,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-11-19T09:39:53.948Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06453265"
    },
    {
      "nct_id": "NCT04172675",
      "title": "A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Urinary Bladder Neoplasms"
      ],
      "interventions": [
        {
          "name": "Erdafitinib",
          "type": "DRUG"
        },
        {
          "name": "Investigator Choice (Gemcitabine)",
          "type": "DRUG"
        },
        {
          "name": "Investigator Choice (Mitomycin C)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 107,
      "start_date": "2020-02-28",
      "completion_date": "2025-02-27",
      "has_results": true,
      "last_update_posted_date": "2026-02-24",
      "last_synced_at": "2026-11-19T09:39:53.948Z",
      "location_count": 22,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Denver, Colorado + 19 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04172675"
    },
    {
      "nct_id": "NCT04506567",
      "title": "Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Multiple Dose of 225Ac-J591 at 45 KBq/kg",
          "type": "DRUG"
        },
        {
          "name": "Multiple Dose of 225Ac-J591 at 55 KBq/kg",
          "type": "DRUG"
        },
        {
          "name": "Multiple Dose of 225Ac-J591 at 65 KBq/kg",
          "type": "DRUG"
        },
        {
          "name": "Fractionated Dose of 225Ac-J591 at 45 KBq/kg",
          "type": "DRUG"
        },
        {
          "name": "Fractionated Dose of 225Ac-J591 at 55 KBq/kg",
          "type": "DRUG"
        },
        {
          "name": "Fractionated Dose of 225Ac-J591 at 60 KBq/kg",
          "type": "DRUG"
        },
        {
          "name": "Fractionated Dose of 225Ac-J591 at 65 KBq/kg",
          "type": "DRUG"
        },
        {
          "name": "Fractionated Dose of 225Ac-J591 at 45 KBq/kg (Prior 177Lu-PSMA-RL)",
          "type": "DRUG"
        },
        {
          "name": "Fractionated Dose of 225Ac-J591 at 50 KBq/kg (Prior 177Lu-PSMA-RL)",
          "type": "DRUG"
        },
        {
          "name": "68Ga-PSMA-HBED-CC injection",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "MALE",
        "summary": "18 Years to 99 Years · Male only"
      },
      "enrollment_count": 60,
      "start_date": "2020-08-18",
      "completion_date": "2026-12",
      "has_results": true,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-11-19T09:39:53.948Z",
      "location_count": 2,
      "location_summary": "Brooklyn, New York • New York, New York",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04506567"
    }
  ]
}